Introduction {#sec1-1}
============

Until today, numerous epidemiological studies have been carried out investigating height and the risk for development of breast cancer and many predictions have been made. There is an association regarding the risk for breast cancer tends to be higher in tall women, although reason for this link is yet to be (McEligot et al., 2008; Kabat et al., 2013; Zhang et al., 2015). In a meta-analysis performed on more than 5 million women (of whom 110,000 women had been diagnosed with breast cancer) each 10 cm increment in height has been observed to increase the risk for cancer by 17% (Zhang et al., 2015). A total of 62,328 women with breast cancer and 83817 control subjects have been evaluated. Each 10 cm increment in genetically predicted height was associated with 21-22% increase in the risk to get breast cancer (Zhang et al., 2015). Looking to the results from these epidemiological studies, it does not mean that all tall women will definitely get cancer. Although the factors associating height and breast cancer are not fully determined, many risk factors are thought to be effective on this association (Kabat et al., 2013).

With underscoring risk of height in development of breast cancer, studies investigating effect of height on progression free survival and overal survival have become a current issue. Recent studies emphasized that anthropometric measurements including neck and waist circumferences and body mass index have prognostic features, although whether height independently influence prognosis is yet to be clarified. The objective of this study is to investigate the correlation of height with prognosis and other prognostic factors in total 393 women aged between 26 and 88 years, diagnosed with stage 1-3 invasive ductal breast cancerand, followed-up and treated in Kayseri Education and Research Hospital.

The mean age at admission was 55.7 of the patients; 77.6 % aged under 65, 56.7 % were postmenopausal, 97.4 % undergone modified radical mastectomy, 47.3 % were AJCC stage II, 36.8 % N0, 46.0 % grade II, 95.4 % received chemotherapy, 81.1 % radiotherapy and 71.5 % hormonotherapy. Height was under 151 cm in 20.8 %, 151-160 cm in 57.3% and over 161 in 21.9% of patients ([Table 1](#T1){ref-type="table"}). Follow-up duration differed between 0.3 and 195.3 months. Mean overal survival (OS) was found as 125.0 (65.6-184.3) months and progression free survival (PFS) as 91.5 (37.7-145.2) months. The rates of 5 and 10-year OS were found as 74.5%and 56.4%, and PFS as 64.5%and 49.2%.

###### 

Patient and Tumor Characteristics According to Their Pretreatment Height (n=393)

  Patient and tumour characteristics   Height (\<151 cm)   Height (151-160cm)   Height (\>160 cm)   P value (\<0.05)
  ------------------------------------ ------------------- -------------------- ------------------- ------------------
  Age (years)                                                                                       0.214
   \<65                                58                  177                  70                  
   =\>65                               24                  48                   16                  
  Menopausal status                                                                                 0.429
   premenopausal                       29                  96                   42                  
   postmenopausal                      52                  128                  43                  
  Tumor localization                                                                                0.854
   right                               43                  115                  47                  
   left                                39                  110                  39                  
  AJCC stage                                                                                        0.011
   stage I                             3                   30                   16                  
   stage II                            48                  107                  31                  
   stage III                           31                  88                   39                  
  Tumor size                                                                                        0.078
   I                                   7                   49                   21                  
   II                                  57                  132                  42                  
   III                                 12                  29                   16                  
   IV                                  6                   15                   7                   
  Lymph node status                                                                                 0.13
   0                                   39                  74                   32                  
   I                                   21                  70                   18                  
   II                                  12                  47                   24                  
   III                                 10                  34                   12                  
  Histologic grade                                                                                  0.525
   I                                   16                  43                   21                  
   II                                  43                  100                  38                  
   III                                 20                  60                   19                  
  ER status                                                                                         0.043
   positive                            37                  73                   40                  
   negative                            41                  147                  43                  
   unknown                             4                   5                    3                   
  PR status                                                                                         0.072
   negative                            37                  95                   27                  
   positive                            38                  123                  55                  
  HER2                                                                                              0.387
   positive                            22                  58                   21                  
   negative                            52                  158                  59                  
  Perinodal involvement                                                                             0.669
   no                                  32                  78                   28                  
   yes                                 50                  146                  58                  
  Lymphovascular invasion                                                                           0.918
   no                                  29                  71                   29                  
   yes                                 52                  149                  56                  
  Surgery                                                                                           0.535
   mastectomy                          79                  221                  83                  
   lumpectomy                          3                   4                    3                   
  Chemotherapy                                                                                      0.562
   yes                                 80                  213                  82                  
   no                                  2                   12                   4                   
  Radiotherapy                                                                                      0.583
   yes                                 13                  42                   19                  
   no                                  69                  183                  67                  
  Hormonotherapy                                                                                    0.129
   yes                                 48                  162                  59                  
   no                                  29                  56                   22                  

Looking at the association of height with other prognostic factors, a significant correlation was found between height and AJCC stage and estrogen status (ER) ([Table 1](#T1){ref-type="table"}). When OS and PFS were assessed according to height, it was found that mean OS was 82.8 and PFS was 86.9 months in cases with height \<150 cm; 160.3 and 86.1 months in cases with height of 151-160 cm; 128.4 and 125.9 months in cases with \>161, respectively.

When in the present study, association of height with other clinico-pathologic factors was examined, a significant correlation was found with stage and estrogen receptor. Although OS was found to be better in patients with a high between 151 and 160 cm than those under 151 cm and over 161 cm, the difference did not reach to statistical significance. Studies report that growth and insulin-like growth factor (IGF1) hormones, genetic, life style and environmental factors impact the effects of height both on the risk for breast cancer and survival. Furthermore, at the cellular level tall people are thought to have more cells, thus the risk for unnatural cell division, namely development of cancer cells may play a role in this condition (McEligot et al., 2008; Kabat et al., 2013; Kawai et al., 2014; Zhang et al., 2015). IGF-1 regulates grotwh both in utero and in childhood. Furthermore, it may present mitotic effect in patients with breast cancer, causing poor prognosis (Zhang et al., 2015). Increased serum level of estrogen may cause increase frequency of both DNA mutation and mitosis, playing a role initiation and progression of breast cancer. In addition, endogenous estrogen which is a hormone playing a central role in the etiology of breast cancer influence timing of puberty, thus affecting height. A positive correlation was found between height and the risk of breast cancer in postmenopausal women, while no such a link was established in premenopausal women (Kabat et al., 2013; Zhang et al., 2015). Looking to anthropometric measurements, in our previous study OS was found to be statistically significantly longer in breast cancer patients with a normal body mass index compared to the low weight and obese patients groups (Cihan, 2014). McEligot et al studied anthropometric measurements (weight and height) on breast cancer patients. The authors found that, overweight was significantly correlated with clinicopathologic/prognostic factors of cancer and suggested that etiologic factors that could be associated with trends, incidence and survival of cancer should be monitored (McEligot et al., 2008).

In conclusion, overal survival was found to be longer in patients with a height between 151 and 160 cm than those under 151 cm and over 161 cm. The reason to not obtain a significant result might be explained by the small number of patients and lack of the evaluation of clinical and pathologic characteristics together with anthropometric measurements in patient population. Further studies are warranted to clarify this association.
